Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy

FHS
May 27, 2024
1:18 pm

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after the successful development of a new alpha-ray therapeutic agent ([At-211] PSMA-5) and confirmation of its efficacy in animal models.

Dangerous antibiotic-resistant bacteria found in China’s ready-to-eat foods

The study reveals high levels of antibiotic-resistant Staphylococcus aureus (MRSA) in ready-to-eat foods across 25 provinces in China, posing a serious public health risk. The

September 11, 2023

Mechanoresilient cancer cells more prone to metastasis

The ability of cancer cells to metastasize, or spread from one part of the body to another, is one of the reasons why cancer can

September 23, 2023

Q&A: FDA’s Peter Marks ready to encourage more accelerated approvals for rare diseases

FDA biologics center director Peter Marks said the agency plans to encourage sponsors to use the accelerated approval pathway, particularly for rare disease treatments, as

August 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.